Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8331035 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL8334546 | 0.86 | KMT2A (0.52) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL11855622 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL25422900 | 0.84 | KMT2A (0.44) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL28346418 | 0.83 | MAPT (0.44) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL18946229 | 0.81 | MEN1 (0.56) | MAPTKMT2AMEN1HSP90AA1ALDH1A1 | |
| SCHEMBL3597390 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL10882422 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL8466527 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL7520916 | 0.79 | KMT2A (0.55) | SMN1; SMN2MAPTLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309038-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2024-09-19 | — | — | US | disclosed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4267568-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022144274-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-07-07 | — | — | WO | disclosed |
| US-7270857-B2 | Liquid crystal composition and liquid crystal element | FUJIFILM CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| US-7270857-B2 | Liquid crystal composition and liquid crystal element | FUJIFILM CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309038-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS3, LGALS1, LGALS3BP | SMN1; SMN2 3245/4885MAPT 2329/4885LMNA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.